Defining the risks of mesenchymal stromal cell therapy

Cytotherapy. 2010 Sep;12(5):576-8. doi: 10.3109/14653249.2010.507330.

Abstract

Abstract We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

MeSH terms

  • Adult Stem Cells / metabolism*
  • Adult Stem Cells / pathology
  • Animals
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Cell Culture Techniques
  • Cell Proliferation
  • Cell Transformation, Neoplastic*
  • Cellular Senescence
  • Clinical Trials as Topic
  • Humans
  • Mesenchymal Stem Cell Transplantation / adverse effects*
  • Mesenchymal Stem Cells / metabolism*
  • Mesenchymal Stem Cells / pathology
  • Mice
  • Risk Factors
  • Stromal Cells / metabolism*
  • Stromal Cells / pathology
  • Stromal Cells / transplantation
  • Telomerase / genetics
  • Telomerase / metabolism

Substances

  • Biomarkers, Tumor
  • Telomerase